Stay updated on Safety of Ipilimumab and Nivolumab in Liver Resection Clinical Trial
Sign up to get notified when there's something new on the Safety of Ipilimumab and Nivolumab in Liver Resection Clinical Trial page.

Latest updates to the Safety of Ipilimumab and Nivolumab in Liver Resection Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check23 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check37 days agoChange DetectedThe page has undergone significant updates, including the removal of detailed information about the PRIME-HCC trial and its procedures, while adding references to the study's collaborators and identifiers.SummaryDifference42%
- Check44 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check80 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check102 days agoChange DetectedThe web page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
- Check109 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.1%
Stay in the know with updates to Safety of Ipilimumab and Nivolumab in Liver Resection Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety of Ipilimumab and Nivolumab in Liver Resection Clinical Trial page.